Showing results (121-130 of 161) with videos related to

Sort By:
Pageof 17
Oncogene|September 2, 2018
An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemiaAlok Swaroop, Jon A Oyer, Christine M Will, et al.
Open Forum Infectious Diseases|November 9, 2019
A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2018Elias B Chahine, Spencer H Durham, Krutika N Mediwala, et al.
Blood|August 2, 2018
Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesisElodie Pronier, Robert L Bowman, Jihae Ahn, et al.
Blood|May 18, 2017
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adultsPaul Milne, Venetia Bigley, Chris M Bacon, et al.
Nature Communications|May 19, 2017
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemiaJean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, et al.
Blood Advances|October 24, 2023
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasmsBenjamin H Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, et al.
Blood|May 4, 2018
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes diseaseOussama Abla, Eric Jacobsen, Jennifer Picarsic, et al.
Open Forum Infectious Diseases|December 5, 2022
A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in Non-Hospital Care Settings in 2021Sarah B Green, Ashley H Marx, Elias B Chahine, et al.
Cancers|November 6, 2020
The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester DiseaseRan Weissman, Eli L Diamond, Julien Haroche, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 21, 2016
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKDRobert Provenzano, Anatole Besarab, Chao H Sun, et al.
Pageof 17